Pfizer begins tender offer for Encysive

By Lisa Kerner

Charlotte, N.C., March 4 - Pfizer Inc. subsidiary Explorer Acquisition Corp. began a $2.35-per-share tender offer for Encysive Pharmaceuticals Inc. in a deal first announced on Feb. 20.

The tender offer is set to expire at midnight ET on March 31 unless extended, Pfizer said in a news release.

Computershare Trust Co., NA is the depositary and paying agent for the tender offer. Dealer manager is Lazard Frères & Co. LLC. Georgeson Inc. is the information agent.

The acquisition, valued at $195 million, is expected to increase Pfizer's presence in the cardio-respiratory arena and add near-term revenue from the European market, it was previously reported.

Pfizer is a pharmaceutical company located in New York.

Encysive is a Houston biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.